Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44056   clinical trials with a EudraCT protocol, of which   7319   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-001963-37
    Sponsor's Protocol Code Number:GED-0301-CD-004
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2016-02-03
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2015-001963-37
    A.3Full title of the trial
    A Phase 3, long-term active treatment extension study of mongersen (GED-0301) in subjects with Crohn?s disease
    Estudio de fase III de extensión del tratamiento activo a largo plazo de mongersen (GED-0301) en sujetos con enfermedad de Crohn
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A long-term extension study to evaluate the drug mongersen (GED-0301) for the treatment of Crohn?s disease
    Estudio de extensión a largo plazo para evaluar el fármaco mongersen (GED-0301) para el tratamiento de la enfermedad de Crohn
    A.3.2Name or abbreviated title of the trial where available
    A long-term study to explore the safety of GED-0301 in Crohn's disease
    Estudio a largo plazo para explorar la seguridad de GED-0301 en la enfermedad de Crohn
    A.4.1Sponsor's protocol code numberGED-0301-CD-004
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCelgene Corporation
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCelgene Corporation
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCelgene Corporation
    B.5.2Functional name of contact pointClinicalTrialDisclosure
    B.5.3 Address:
    B.5.3.1Street Address9225 Indian Creek Parkway, Suite 900
    B.5.3.2Town/ cityOverland Park, Kansas
    B.5.3.3Post code66210
    B.5.3.4CountryUnited States
    B.5.4Telephone number+34914229000
    B.5.5Fax number+19132660394
    B.5.6E-mailClinicalTrialDisclosure@celgene.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMongersen
    D.3.2Product code GED-0301
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNmongersen
    D.3.9.1CAS number 1443994-98-6
    D.3.9.2Current sponsor codeGED-0301
    D.3.9.4EV Substance CodeSUB30963
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeantisense-oligonucleotide
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Active Crohn's disease
    Enfermedad de Crohn activa
    E.1.1.1Medical condition in easily understood language
    Crohn?s disease (an Inflammatory Bowel Disease)
    Enfermedad de Crohn (enfermedad intestinal inflamatoria)
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 18.1
    E.1.2Level LLT
    E.1.2Classification code 10021315
    E.1.2Term Ileitis terminal
    E.1.2System Organ Class 100000004856
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the long-term safety of oral GED-0301 in subjects with Crohn?s disease
    Evaluar la seguridad a largo plazo de GED-0301 por vía oral en sujetos con enfermedad de Crohn (EC)
    E.2.2Secondary objectives of the trial
    Secondary objectives are not included in this study.
    En este estudio no se incluyen objetivos secundarios.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Subject is a male or female ? 18 years of age at the time of signing the informed consent form (ICF).
    2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
    3. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
    4. Subject must have completed through Week 12 in the previous GED-0301 study AND either:
    Completed participation through the last study treatment visit
    at Week 52 in Study GED-0301-CD-002 or at Week 12 in Study GED-0301-CD-003 OR Met the ?early escape criteria? and were discontinued after Week 12 in Study GED-0301-CD-002.
    5. Females of childbearing potential (FCBP) must have a negative pregnancy test at screening and enrollment (Visits 1 and 2). While on IP and for at least 28 days after taking the last dose of IP, FCBP who engage in activity in which conception is possible must use one of the approved contraceptive options
    6. Male subjects when engaging in sexual activity with females who are able to become pregnant must use barrier contraception while on IP and for at least 28 days after the last dose.
    1. El sujeto es un hombre o una mujer ? 18 años de edad en el momento de firmar el formulario de consentimiento informado (FCI).
    2. El sujeto debe entender y firmar de forma voluntaria un FCI antes de realizar cualquier evaluación/procedimiento relacionado con el estudio.
    3. El sujeto está dispuesto y es capaz de cumplir el calendario de visitas del estudio y cualquier otro requisito del protocolo.
    4. El sujeto debe haber concluido hasta la semana 12 del anterior estudio de GED-0301 Y o bien:
    Haber concluido su participación hasta la última visita del tratamiento del estudio en la semana 52 del estudio GED-0301-CD-002 o en la semana 12 del estudio GED-0301-CD-003 O BIEN haber cumplido los ?criterios de retirada anticipada? y ser discontinuados tras la semana 12 del estudio GED-0301-CD-002.
    5. Las mujeres en edad fértil (MEF) deben presentar una prueba de embarazo negativa en el momento de la selección y de la inscripción (visitas 1 y 2). Mientras reciban el PEI y durante al menos 28 días después de tomar la última dosis del PEI, las MEF que participen en una actividad en la que sea posible la concepción deben usar una de las opciones anticonceptivas aprobadas
    6. Los sujetos hombres que tengan actividad sexual con mujeres fértiles deben usar un anticonceptivo de barrera mientras tomen el PEI y durante al menos 28 días después de la última dosis.
    E.4Principal exclusion criteria
    1. Subject had experienced a serious adverse event related to the IP while participating in the previous Phase 3 GED-0301 study.
    2. Subject has any continuing serious medical condition, laboratory abnormality, or psychiatric illness that occurred while participating in the previous Phase 3 GED-0301 study.
    3. Subject has or had a flare or worsening of CD that, in the opinion of the Investigator, would not be in the best interest for the subject to participate in this long-term active treatment study.
    4. Subject has initiated biologic agents, such as TNF-? blockers or integrin antagonists.
    5. Subject has been diagnosed with colorectal cancer or colorectal dysplasia (with the exception of adenomatous colonic polyps that have been completely resected) while participating in the previous Phase 3 GED-0301 study.
    6. Subject has a newly diagnosed malignancy while participating in the previous Phase 3 GED-0301 study.
    7. Subject is pregnant or breastfeeding.
    8. Subject has been newly diagnosed with substance abuse.
    9. Subject has developed a known hypersensitivity to oligonucleotides, GED-0301 or any ingredient in the IP.
    1. El sujeto ha experimentado un acontecimiento adverso grave (AAG) relacionado con el PEI mientras estaba participando en el anterior estudio de fase III de GED-0301.
    2. El sujeto tiene alguna afección médica grave, anomalía analítica o enfermedad psiquiátrica continuada que se produjo mientras estaba participando en el estudio anterior de fase III de GED-0301.
    3. El sujeto tiene o ha tenido una exacerbación o un empeoramiento de la EC que, en opinión del investigador, hace que participar en este estudio de tratamiento activo a largo plazo no sea lo más conveniente para el sujeto.
    4. El sujeto ha iniciado el tratamiento con fármacos biológicos, como los bloqueadores del TNF-? o los antagonistas de las integrinas.
    5. Al sujeto se le diagnosticó cáncer colorrectal o displasia colorrectal (a excepción de pólipos adenomatosos de colon que se hayan extirpado por completo) mientras participaba en el estudio anterior de fase III de GED-0301.
    6. Al sujeto se le diagnosticó por primera vez una neoplasia maligna mientras participaba en el estudio anterior de fase III de GED-0301. (A pesar de ello, se permitirá a los sujetos entrar en este estudio según cada caso individual tras la discusión con el promotor).
    7. La sujeto está embarazada o en periodo de lactancia.
    8. Al sujeto se le ha diagnosticado recientemente abuso de sustancias.
    9. El sujeto ha desarrollado hipersensibilidad conocida a los oligonucleótidos, a GED-0301 o a cualquier excipiente del PEI.
    E.5 End points
    E.5.1Primary end point(s)
    Safety of GED-0301, assessed by type, frequency and severity of adverse events, and its relationship to investigational product, discontinuation due to adverse events, and clinically significant changes in electrocardiograms (ECGs), vital signs, and/or laboratory findings
    La evaluación de la seguridad de GED-0301, evaluada según el tipo, la frecuencia y la intensidad de los acontecimientos adversos y su relación con el producto en investigación (PEI), la interrupción a consecuencia de los acontecimientos adversos y los cambios clínicamente significativos de los electrocardiogramas (ECG), las constantes vitales y/o los hallazgos en los análisis clínicos
    E.5.1.1Timepoint(s) of evaluation of this end point
    Through Week 208 and 4 weeks postdose
    Hasta la semana 208 y 4 semanas después de la dosis
    E.5.2Secondary end point(s)
    Secondary endpoints are not included in this study.
    En este estudio no se incluyen criterios de valoración secundarios
    E.5.2.1Timepoint(s) of evaluation of this end point
    not applicable
    No procede
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial5
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA311
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Austria
    Belgium
    Bulgaria
    Canada
    Croatia
    Czech Republic
    Denmark
    Estonia
    France
    Germany
    Greece
    Hungary
    Israel
    Italy
    Korea, Republic of
    Latvia
    Netherlands
    New Zealand
    Norway
    Poland
    Romania
    Russian Federation
    Serbia
    Slovakia
    South Africa
    Spain
    Sweden
    Switzerland
    Turkey
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    End of Study is defined as either the date of the LVLS to complete the post-treatment follow-up, or the date of receipt of the last data point from the LS that is required for primary, secondary and/or exploratory analysis, as prespecified in the protocol, whichever is the later date.
    El fin del estudio se define bien como la fecha de la última visita del último sujeto que concluya el seguimiento tras el tratamiento, o bien como la fecha de recepción del último momento de recogida de datos procedente del último sujeto que sea necesario para el análisis principal y/o el análisis exploratorio, tal y como se especificó previamente en el protocolo, la fecha que sea más tardía.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years4
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1343
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 71
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state19
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 452
    F.4.2.2In the whole clinical trial 1414
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Ninguno
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-04-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-03-21
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2017-10-19
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Sep 19 12:42:32 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA